Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases)
Roxane Domain,Seda Seren,Uwe Jerke,Manousos Makridakis,Kuan-Ju Chen,Jérôme Zoidakis,Moez Rhimi,Xian Zhang,Tillia Bonvent,Cécile Croix,Loïc Gonzalez,Dedong Li,Jessica Basso,Christophe Paget,Marie-Claude Viaud-Massuard,Gilles Lalmanach,Guo-Ping Shi,Ali Aghdassi,Antonia Vlahou,Patrick P. McDonald,Isabelle Couillin,Rich Williams,Ralph Kettritz,Brice Korkmaz
DOI: https://doi.org/10.1016/j.bcp.2024.116114
IF: 6.1
2024-09-30
Biochemical Pharmacology
Abstract:An uncontrolled activity of neutrophil serine proteases (NSPs) contributes to inflammatory diseases. Cathepsin C (CatC) is known to activate NSPs during neutrophilic differentiation and represents a promising pharmacological target in NSP-mediated diseases. In humans, Papillon-Lefèvre syndrome (PLS) patients have mutations in their CTSC gene, resulting in the complete absence of CatC activity. Despite this, low residual NSP activities are detected in PLS neutrophils (<10% vs healthy individuals) , suggesting the involvement of CatC-independent proteolytic pathway(s) in the activation of proNSPs. This prompted us to characterize CatC-independent NSP activation pathways by blocking proCatC maturation. In this study, we show that inhibition of intracellular CatS almost completely blocked CatC maturation in human promyeloid HL-60 cells. Despite this, NSP activation was not significantly reduced, confirming the presence of a CatC-independent activation pathway involving a CatC-like protease that we termed NSPs-AAP-1. Similarly, when human CD34 + progenitor cells were treated with CatS inhibitors during neutrophilic differentiation in vitro , CatC activity was nearly abrogated but ∼30% NSP activities remained, further supporting the existence of NSPs-AAP-1. Our data indicate that NSPs-AAP-1 is a cysteine protease that is inhibited by reversible nitrile compounds designed for CatC inhibition. We further established a proof of concept for the indirect, although incomplete, inhibition of NSPs by pharmacological targeting of CatC maturation using CatS inhibitors. This emphasizes the potential of CatS as a therapeutic target for inflammatory diseases. Thus, preventing proNSP maturation using a CatS inhibitor, alone or in combination with a CatC/NSPs-AAP-1 inhibitor, represents a promising approach to efficiently control the extent of tissue injury in neutrophil-mediated inflammatory diseases.
pharmacology & pharmacy